Forward-looking Statement
This presentation contains "forward-looking statements" within the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding VaxGen’s expected cash and revenue, the timing and progress of completion of development efforts for VaxGen’s anthrax, smallpox, or HIV vaccine candidates, the need for clinical trials to support licensure of any of the vaccine candidates, and the timing and progress of the company's Phase III clinical trial of AIDSVAX in Thailand. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Reference should be made to VaxGen's Material Change Report on Form 8-K, filed with the Securities and Exchange Commission (SEC) on October 14, 2003, under the heading “Risk Factors” and “Business” for a more detailed description of such factors. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this presentation. VaxGen undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this presentation except as required by law.